Drug information provided by: Merative, Micromedex®
Lazertinib is used in combination with amivantamab as a first-line treatment for non-small cell lung cancer (NSCLC) that is metastatic (cancer that has spread) or cannot be removed by surgery in patients who have an abnormal epidermal growth factor receptor (EGFR) gene (exon 19 deletions or exon 21 L858R substitution mutations). Your doctor will perform a test before you take this medicine.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Oct. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.